Agios Pharmaceuticals (AGIO)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
for [[ item.sessionDateDisplayLong ]]
Fiscal Year End Date: 12/31
| 12-2024 | 09-2024 | 06-2024 | 03-2024 | 12-2023 | |
| Assets | |||||
| Current Assets | |||||
| Cash & Cash Equivalents | 76,247 | 253,730 | 84,518 | 118,764 | 88,205 |
| Marketable Securities | 817,463 | 751,027 | 485,374 | 479,227 | 688,723 |
| Receivables | 4,109 | 3,118 | 3,762 | 3,453 | 2,810 |
| Inventories | 27,616 | 26,429 | 23,937 | 23,070 | 19,076 |
| TOTAL | $965,600 | $1,074,189 | $632,127 | $663,627 | $833,835 |
| Non-Current Assets | |||||
| PPE Net | 11,675 | 11,819 | 12,726 | 14,119 | 15,382 |
| Investments And Advances | 638,321 | 655,889 | 75,404 | 116,301 | 29,435 |
| Other Non-Current Assets | 47,603 | 49,897 | 52,806 | 55,662 | 58,466 |
| TOTAL | $697,599 | $717,605 | $140,936 | $186,082 | $103,283 |
| Total Assets | $1,663,199 | $1,791,794 | $773,063 | $849,709 | $937,118 |
| Liabilities | |||||
| Current Liabilities | |||||
| Accounts payable and accrued liabilities | 16,643 | 17,143 | 10,035 | 11,155 | 9,780 |
| Accrued Expenses | 46,861 | 33,307 | 36,742 | 25,129 | 43,167 |
| TOTAL | $81,156 | $119,451 | $62,637 | $51,691 | $67,955 |
| Non-Current Liabilities | |||||
| Other Non-Current Liabilities | 41,087 | 45,671 | 49,916 | 54,096 | 58,144 |
| TOTAL | $41,087 | $45,671 | $49,916 | $54,096 | $58,144 |
| Total Liabilities | $122,243 | $165,122 | $112,553 | $105,787 | $126,099 |
| Shareholders' Equity | |||||
| Shares Outstanding, K | 57,296 | 57,030 | 56,893 | 56,773 | 56,195 |
| Common Shares | 73 | 73 | 73 | 73 | 72 |
| Retained earnings | -148,924 | -52,401 | -1,000,316 | -904,198 | -822,649 |
| Other shareholders' equity | -2,004 | 2,934 | -1,531 | -1,573 | -927 |
| TOTAL | $1,540,956 | $1,626,672 | $660,510 | $743,922 | $811,019 |
| Total Liabilities And Equity | $1,663,199 | $1,791,794 | $773,063 | $849,709 | $937,118 |